Trump's promise of light regulation could solve one of Citi's biggest problems.

UBS tells investors that Citi (C) would be a beneficiary of a Trump victory, particularly given its lagged performance, despite being a ...

Yigal Nochomovitz, an analyst from Citi, maintained the Hold rating on Krystal Biotech ... that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin ...